4.6 Article

Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer

Journal

AGING-US
Volume 13, Issue 23, Pages 25518-25549

Publisher

IMPACT JOURNALS LLC

Keywords

colorectal cancer; immune signature; prognosis; immunotherapy; precision medicine

Funding

  1. National Key R&D Program of China [2019YFA0110300, 2020YFA0509400]
  2. National Natural Science Foundation of China [82071745]
  3. Science and Technology Program of Guangzhou [202002030069]
  4. Guangdong project [2019QN01Y212]

Ask authors/readers for more resources

This study utilized gene expression profiles and clinical characteristics to construct an immune-related genes signature for evaluating clinical outcomes and immune features of CRC patients. The research found that CRC patients with low immune risk scores may benefit more from immunotherapy, while those with high risk scores could potentially benefit from specific drug treatments.
Background: Globally, colorectal cancer (CRC) is one of the most lethal malignant diseases. However, the currently approved therapeutic options for CRC failed to acquire satisfactory treatment efficacy. Tailoring therapeutic strategies for CRC individuals can provide new insights into personalized prediction approaches and thus maximize clinical benefits. Methods: In this study, a multi-step process was used to construct an immune-related genes (IRGs) based signature leveraging the expression profiles and clinical characteristics of CRC from the Gene Expression Omnibus (GEO) database and the Cancer Genome Atlas (TCGA) database. An integrated immunogenomic analysis was performed to determine the association between IRGs with prognostic significance and cancer genotypes in the tumor immune microenvironment (TIME). Moreover, we performed a comprehensive in silico therapeutics screening to identify agents with subclass-specific efficacy. Results: The established signature was shown to be a promising biomarker for evaluating clinical outcomes in CRC. The immune risk score as calculated by this classifier was significantly correlated with over-riding malignant phenotypes and immunophenotypes. Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and Scrizotinib might have potential therapeutic implications in the immune risk score-high CRCs. Conclusions: Overall, this IRGs-based signature not only afforded a useful tool for determining the prognosis and evaluating the TIME features of CRCs, but also shed new light on tailoring CRCs with precise treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available